Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Assessment of the Usefulness of SMI (Superb Vascular Imaging) for the Characterisation of Pancreatic Cystic Tumours (IMAKYST) (IMAKYST)

13 de junio de 2026 actualizado por: GCS Ramsay Santé pour l'Enseignement et la Recherche

A cystic lesion is an abnormal cavity formed within tissue or an organ, which may contain a liquid, semi-solid or gaseous substance.

There are different types of pancreatic cystic lesions: lesions that may become cancerous and completely benign lesions that do not require monitoring, such as serous cystadenomas (SCs) and pseudocysts.

Diagnostic difficulties mean that one in three patients with a SC undergoes unnecessary surgery with significant morbidity and mortality (risk of death). Currently, needle-based confocal laser endomicroscopy (nCLE) is the gold standard technique for the diagnosis of SC.

SC is a lesion characterised by an extensive network of small blood vessels present in all the cyst walls and throughout the cyst's peripheral capsule. SMI (Superb Vascular Imaging) is a new ultrasound mode that improves the visibility of blood flow in the vessels without the injection of contrast medium (a diagnostic agent used for certain medical imaging examinations, most often administered intravenously), unlike nCLE.

The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new EUS Aplio i800 console (Canon-Olympus), which is CE marked.

To date, no data has been published on the potential of SMI to characterise and diagnose CS. This is why this clinical investigation is being conducted.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Pancreatic cysts are becoming increasingly common in the general population. They are most often discovered incidentally during cross-sectional abdominal imaging.

There are different types of pancreatic cystic lesions, each with distinct risks of progression. Lesions with the potential for malignant transformation are typically mucinous lesions (papillary intraductal mucinous neoplasms of the pancreas [PIMN] and mucinous cystic neoplasms [MCN]), formerly known as mucinous cystadenomas), whereas non-mucinous lesions (serous cystadenomas [SCs] and pseudocysts) are entirely benign and do not require monitoring.

SC typically presents as a solitary cyst with no communication with the Wirsung duct, appearing microcystic with central calcification. This typical appearance is not always present, and SC can mimic a mucinous lesion. In such cases, imaging and echoendoscopy findings are not discriminatory. Histological and biochemical analysis of the fluid obtained during cyst aspiration may be helpful, but the specificity is usually insufficient to make a definitive decision regarding the absence of surgery and the need for monitoring. These diagnostic difficulties mean that one in three patients with SC undergo unnecessary surgery, with significant morbidity and mortality.

There are currently two highly effective techniques for diagnosing SC:

  • Endocystic microbiopsy, which has a diagnostic accuracy of nearly 100% but a high complication rate (around 10%). It is no longer recommended except in exceptional cases.
  • Needle-based confocal laser endomicroscopy (nCLE), which has 100% specificity for the diagnosis of SC.

SC is a lesion characterised by intense microvascularisation present in all the cyst walls and throughout the entire peripheral capsule of the cyst. SMI is a new ultrasound modality capable of visualising microvascular flow without the need for contrast injection, unlike nCLE.

The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new Aplio i800 EUS console (Canon-Olympus).

To date, no data has been published on the potential of SMI for characterising and diagnosing SC. This is why this clinical investigation is being conducted.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Bertrand NAPOLEON, MD
  • Número de teléfono: + 33 4 78 75 67 43
  • Correo electrónico: dr.napoleon@wanadoo.fr

Ubicaciones de estudio

      • Lyon, Francia, 69008
        • Reclutamiento
        • Hôpital privé Jean Mermoz
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Patient referred for confocal microscopy (nCLE) assessment of a pancreatic cyst of unknown origin
  • Patient with a cyst measuring more than 15 mm in diameter and at least one cyst cavity measuring ≥ 5 mm (to allow nCLE to be performed)
  • Patient registered with or covered by the National Health Service
  • French-speaking patient who has signed an informed consent form

Exclusion Criteria:

  • Patient with calcifying chronic pancreatitis
  • Presence of a communication with the main pancreatic duct on MRI or endoscopic ultrasound
  • Patient whose lesion meets criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration)
  • Patient with a contraindication to endoscopic ultrasound-guided puncture (haemostatic disorder)
  • Patient with a known allergy to fluorescein (used in nCLE)
  • Pregnant woman
  • Patient under legal guardianship: adults under guardianship, curatorship or other legal protection, or deprived of their liberty by judicial or administrative order
  • Hospitalised patient without consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: SMI group
Intervention involves acquiring B-mode images of the pancreatic cyst using SMI
B-mode imaging of pancreatic cysts with SMI using the new Aplio i800 EUS console (Canon-Olympus)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
SMI specificity
Periodo de tiempo: Day 0
SMI specificity is expressed as a percentage. Specificity is defined as the number of true negatives (negative diagnoses in patients without SC) divided by the total number of patients without SC.
Day 0

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de mayo de 2026

Finalización primaria (Estimado)

30 de noviembre de 2027

Finalización del estudio (Estimado)

30 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

13 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de junio de 2026

Publicado por primera vez (Actual)

18 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 2026-A00624-47

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir